Reviva Pharmaceuticals (NASDAQ:RVPH) Lowered to “Hold” Rating by D. Boral Capital

Reviva Pharmaceuticals (NASDAQ:RVPH) was downgraded by equities researchers at D. Boral Capital from a “buy” rating to a “hold” rating in a report issued on Thursday.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Thursday, January 22nd. Finally, Chardan Capital reiterated a “buy” rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $3.33.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $0.24 on Thursday. The company’s fifty day moving average is $0.29 and its two-hundred day moving average is $0.44. Reviva Pharmaceuticals has a 52-week low of $0.20 and a 52-week high of $1.35. The firm has a market capitalization of $28.11 million, a price-to-earnings ratio of -0.53 and a beta of 0.10.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals in the 1st quarter valued at approximately $58,000. XTX Topco Ltd boosted its stake in Reviva Pharmaceuticals by 63.6% during the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after acquiring an additional 63,893 shares during the last quarter. Lido Advisors LLC acquired a new position in Reviva Pharmaceuticals during the third quarter valued at approximately $37,000. Finally, Millennium Management LLC increased its stake in Reviva Pharmaceuticals by 15.0% in the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after purchasing an additional 223,178 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.